Table 1.
Name | Trade Name | FDA Approval |
Type | Administration | Application | Antimicrobial Activity |
---|---|---|---|---|---|---|
Vancomycin | Vanocin | 1983 | Heptapeptide | Oral | Bacterialinfections | G-positive bacteria |
Bacitracin | Baciim | 1997 | Cyclic peptide | Topical | Skin and eye infections | G-positive bacteria |
Daptomycin | Cubicin | 2003 | Cyclic lipopeptide | Intravenous | Skin infections | G-positive bacteria |
Telavancin | Vibativ | 2009 | Lipoglycopeptide | Intravenous | Skin infections | G-positive bacteria |
Oritavancin | Orbactiv | 2014 | Lipoglycopeptide | Intravenous | Skin infections | G-positive bacteria |
Dalbavancin | Dalvance | 2014 | Lipoglycopeptide | Intravenous | Skin infections | G-positive bacteria |